CASI Pharmaceuticals Inc. reported its financial results for the first quarter of 2025, showing significant growth in revenues and an expansion in net loss. The company achieved revenues of $6.2 million, marking an 82% increase from the $3.4 million recorded in the same period last year. This substantial growth reflects the effective execution of its commercial strategy initiated in the latter half of 2024. However, the net loss for the quarter rose by 14% to $10.8 million, compared to $9.5 million in the previous year, primarily due to increased legal fees associated with ongoing arbitration with Juventas and a dispute with Acrotech. Research and development expenses decreased by 24% to $1.9 million from $2.5 million in the first quarter of the previous year, largely because annual regulatory filing fees for the generic portfolio were fully paid in the prior-year quarter. Conversely, general and administrative expenses escalated by 60% to $7.7 million from $4.8 million in the same period last year, mainly due to the aforementioned legal fees. CASI Pharmaceuticals also provided an update on its strategic business operations, highlighting the planned divestiture of assets in China. The company has entered into a definitive agreement with Kaixin Pharmaceuticals to sell 100% equity interests in two subsidiaries in China for a total purchase price of $20.0 million, which includes the assumption of up to $20.0 million of company debt. Post-transaction, CASI expects to retain rights related to its core products such as CID-103 in Japan and non-Asian regions, EVOMELA ®, FOLOTYN ®, CNCT19, and CB-5339, aiming to sharpen its strategic focus and enhance long-term value delivery. As of March 31, 2025, CASI had cash and cash equivalents of $10.9 million, a decrease from $13.5 million as of December 31, 2024.